BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
AstraZeneca
Citi
Healthtrust
Deloitte
US Army
Baxter
Chinese Patent Office
Julphar

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,727,253

« Back to Dashboard

Which drugs does patent 6,727,253 protect, and when does it expire?

Patent 6,727,253 protects TOTECT and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.
Summary for Patent: 6,727,253
Title: Treatment of accidental extravasation of anthracyclines
Abstract:The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.
Inventor(s): Langer; Seppo W. (Gentofte, DK), Jensen; Peter B. (Farum, DK), Sehested; Maxwell (Copenhagen, DK)
Assignee: Antianthra APS (Farum, DK)
Application Number:09/893,521
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,727,253

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Clinigen Hlthcare TOTECT dexrazoxane hydrochloride INJECTABLE;INJECTION 022025-001 Sep 6, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,727,253

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1999 00355Mar 12, 1999

International Patents Family Members for US Patent 6,727,253

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 0009473 ➤ Subscribe
Canada 2367240 ➤ Subscribe
China 1346275 ➤ Subscribe
China 1199644 ➤ Subscribe
Germany 1162981 ➤ Subscribe
Germany 60010241 ➤ Subscribe
Denmark 1162981 ➤ Subscribe
European Patent Office 1162981 ➤ Subscribe
European Patent Office 1459752 ➤ Subscribe
Hong Kong 1043054 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Chubb
Covington
Johnson and Johnson
Teva
Citi
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot